Edition:
United States

Veloxis Pharmaceuticals A/S (VELOX.CO)

VELOX.CO on Copenhagen Stock Exchange

1.04DKK
10:59am EDT
Change (% chg)

kr.-0.01 (-0.95%)
Prev Close
kr.1.05
Open
kr.1.03
Day's High
kr.1.05
Day's Low
kr.1.03
Volume
342,172
Avg. Vol
1,054,528
52-wk High
kr.1.49
52-wk Low
kr.0.93

VELOX.CO

Chart for VELOX.CO

About

Veloxis Pharmaceuticals A/S, formerly LifeCycle Pharma A/S, is a Denmark-based company active in the biotechnology and pharmaceutical industry. It is primarily focused on the development of its transplant immunosuppression product candidate, LCP-Tacro. LCP-Tacro is being developed as a once-daily dosage version of tacrolimus for... (more)

Overall

Beta: 0.04
Market Cap(Mil.): kr.1,777.23
Shares Outstanding(Mil.): 1,707.99
Dividend: --
Yield (%): --

Financials

  VELOX.CO Industry Sector
P/E (TTM): -- 142.93 17.37
EPS (TTM): -0.04 -- --
ROI: -54.58 2.34 -5.89
ROE: -86.91 0.22 -5.30

BRIEF-Veloxis Pharmaceuticals Q1 operating loss narrows to $5.2 mln

* VELOXIS MAINTAINS ITS 2017 OUTLOOK OF OPERATING LOSS BEFORE THE RECOGNITION OF INCOME FROM LICENSE AGREEMENTS AND BEFORE ACCOUNTING FOR STOCK COMPENSATION TO BE IN THE RANGE OF USD 5 – 15 MILLION.

May 17 2017

BRIEF-Veloxis increases share capital in connection with exercise of warrants

* CAPITAL INCREASED BY 1,000,000 NEW SHARES WITH A NOMINAL VALUE OF DKK 0.10 EACH CORRESPONDING TO NOMINALLY DKK 100,000 AS A CONSEQUENCE OF EXERCISE OF WARRANTS

Apr 04 2017

BRIEF-Veloxis Pharmaceuticals announces New Jersey office closure

* US subsidiary, Veloxis Pharmaceuticals Inc., has decided to close its office in Edison, New Jersey effective February 28, 2017

Feb 28 2017

BRIEF-Veloxis Pharmaceuticals announces amended and restated loan and security agreement

* Agreed to amend and restate terms of its previously announced loan and security agreement with Lundbeckfond Invest A/S and Novo A/S.

Feb 08 2017

More From Around the Web

Earnings vs. Estimates